Profit from IBM’s spinoff opportunity

Profit from IBM’s spinoff opportunity

Improved sales led to a 0.3% revenue bump for this company during the most-recent quarter. It also beat the consensus earnings estimate.

A recent spinoff offered its investors an interesting opportunity going forward.

Meanwhile the stock trades at just 11.5 times the company’s 2022 earnings forecast.

INTERNATIONAL BUSINESS… Read More

Two Canadian ETFs hold most of Canada’s best stocks

Two Canadian ETFs hold most of Canada’s best stocks

Today, we look at two Canadian ETFs that hold many of the Canadian stocks we recommend for 2021. iShares S&P/TSX 60 Index ETF and iShares Canada Select Dividend Index ETF mirror, respectively, sub-indexes holding the 60 most-heavily trades stocks and 30 of the highest-yielding dividend stocks… Read More

New products spur Boston Scientific

There’s little doubt that the developing world’s aging population will continue to spend more on medical services for years to come. Medical device makers are well positioned to capture a share of that increased spending.
We continue to see attractive investment opportunities for our subscribers among… Read More

AbbVie expands in the medical aesthetics market

We continue to see attractive investment opportunities for our subscribers in top drug stocks—and that includes AbbVie Inc. Meanwhile, the company is also a major player in medical aesthetics—a profitable niche between the beauty industry and plastic surgery.
ABBVIE INC., $115.53, (New York symbol ABBV; TSINetwork… Read More

AbbVie’s diversification pays off

We continue to see attractive investment opportunities for our subscribers in top drug stocks—and that includes AbbVie Inc.
Over the years, we’ve found that spinoffs are about as close as you can get to a sure thing in investing. It’s one key reason why we think… Read More